Abstract 3301
Background
Different therapeutic options have been approved in the last decade for the management of mCRPC. New prognosis biomarkers are necessary in the clinical practice to determine the optimal treatment sequence. In recent years, a number of studies have suggested an association between SNPs in androgen related-genes and outcome.
Methods
Abi or Enza-treated mCRPC patients (pts) in the PROREPAIR-B study (NCT03075735) were included. Nine SNPs within the six candidate genes, namely, CYP17A1 (rs2486758), SCLO2B1 (rs1077858), SRD5A1 (rs3736316 and rs3822430), SRD5A2 (rs2300700), HSD3B1 (rs1047303) and SULT1E1 (rs10019305, rs4149534 and rs3775777) were genotyped. Genotyping was performed using predesigned and custom Taqman SNP genotyping assays (Applied Biosystems, Foster City, CA) and 7500 Fast Real-Time PCR systems (Applied Biosystems, Foster City, CA). The allele calls were identified by specific software. Associations between genotypes and overall survival (OS), time to PSA progression (TTPP) and time to castration resistance (TCR) were calculated with bivariate Cox-regression models including line of treatment. Kaplan Meier estimates of survival were calculated.
Results
322 pts treated with Abi (n = 259; 80.4%) or Enza (n = 63; 19.6%) were included in the analysis. Pts received Abi/Enza as first (n = 209; 64.9%), second (n = 111; 34.5%) or third (n = 2; 0.6%) line. Median OS was 25.9 m (95% CI: 23.5-28.3); median TTPP was 7 m (95% CI: 6.1-7.9) and median TCR was 29.1 m (95% CI: 24.1-34.1). rs3822430 SRD5A1 (0.82 [95% CI: 0.72-0.95]; p = 0.007) an rs3736316 SRD5A1 (HR: 0.86 [0.74-0.99]; p = 0.033) showed a significant association with OS. rs2486758 CYP17A1 (HR: 0.78 [0.64-0.95]; p = 0.014) showed a significant association with TCR. No SNPs showed an association with TTPP.
Conclusions
In our series (PROREPAIR-B) not significant associations were observed between most of the evaluated SNPs and outcomes in mCRPC patients treated with Abi or Enza.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centro Nacional de Investigaciones Oncológicas (CNIO).
Funding
Has not received any funding.
Disclosure
D. Lorente: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen-Cilag; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas Pharma; Travel / Accommodation / Expenses: Celgene. R. Lozano Mejorada: Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen-Cilag; Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Astellas-Pharma. N. Romero Laorden: Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas-Pharma; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen-Cilag; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi-Aventis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: PharmaMar; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche. A. Medina Colmenero: Honoraria (self), Travel / Accommodation / Expenses: Janssen-Cilag; Honoraria (self): Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Janssen-Cilag; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Novartis. J. Puente: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (self): Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen-Cilag; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: Pierre Fabre; Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy: Kiowa; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Eisai; Advisory / Consultancy: Eusa Pharma; Advisory / Consultancy: Boehringer Ingelheim. R. Villatoro: Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas-Pharma; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ipsen; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol. S. Vazquez Estevez: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim. J.M. Piulats: Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen Oncology; Advisory / Consultancy: Astella Pharma; Advisory / Consultancy: VCN Biosciences; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Clovis Oncology; Research grant / Funding (self): Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Research grant / Funding (self): Incyte; Research grant / Funding (self): MedImmune; Research grant / Funding (self): EMD Serono; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Bristol-Myers Squibb. N. Lainez: Advisory / Consultancy: Astellas-Pharma; Advisory / Consultancy: Roche; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer. A. González del Alba: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Astellas-Pharma; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen Oncology; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: MSD Oncology; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Novartis; Advisory / Consultancy: Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy: EUSA Pharma; Advisory / Consultancy: Ipsen; Full / Part-time employment: SERMAS. D. Olmos Hidalgo: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self): Sanofi; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Clovis Oncology; Travel / Accommodation / Expenses: Ipsen; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Tokai Pharmaceuticals. E. Castro: Honoraria (self), Travel / Accommodation / Expenses: Astellas-Pharma; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (institution): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract